Please ensure Javascript is enabled for purposes of website accessibility

How ResMed Blew Past Expectations With Its Q1 Results

By Keith Speights - Oct 25, 2019 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The healthcare company easily topped Wall Street revenue and earnings estimates.

Despite a horrible start, 2019 has turned out to be a reasonably good year so far for ResMed (RMD -0.72%). The healthcare company has consistently beaten Wall Street earnings estimates in recent quarters and delivered solid growth.

ResMed announced its fiscal 2020 first-quarter results after the market closed on Thursday, and the company kept its streak going with more good news. Here are the highlights from ResMed's Q1 update.

Woman asleep in bed using a Continuous Positive Airway Pressure (CPAP) machine.

Image Source: Getty Images.

By the numbers

ResMed announced Q1 revenue of $681.1 million, a 16% increase from the $588.3 million reported in the same quarter of the previous year. This result easily beat the average analyst revenue estimate of $660.7 million.

The company announced first-quarter net income of $120.1 million, or $0.83 per share, based on generally accepted accounting principles (GAAP). This represented a 14% increase from the $105.7 million, or $0.73 per share, reported in the same quarter of 2018. 

ResMed recorded adjusted net income in the first quarter of $0.93 per share. This reflected a 15% year-over-year increase. It also topped the consensus Wall Street adjusted earnings per share (EPS) estimate of $0.87.

Behind the numbers

ResMed's strong revenue growth stemmed primarily from U.S., Canada, and Latin America, with sales climbing 11% in the regions. Software-as-a-service (SaaS) revenue soared 83% year over year, to $86.9 million, while sleep and respiratory care revenue jumped 13% higher, to $370.3 million. The SaaS total was boosted by ResMed's acquisition of long-term and post-acute care software provider MatrixCare.

Growth wasn't nearly as strong in Europe, Asia, and other markets, though. ResMed reported total revenue in the regions of $223.9 million, up only 4% year over year.

The company's bottom-line growth trailed revenue growth slightly for a couple of reasons. Operating expenses increased significantly from the prior-year period. ResMed also reported $10.5 million in other net expenses in the third quarter, well above the $2.8 million posted in the same quarter of last year.

Looking ahead

ResMed CEO Mick Farrell said that the company is "driving forward every facet of our business, leading the innovation of devices and software that improve health outcomes, create efficiencies, and reduce overall healthcare system costs. We're well on our way to improving 250 million lives in out-of-hospital healthcare in 2025."

Although ResMed might not be known as a great dividend stock, the company has steadily increased its dividend payout in recent years. ResMed's board of directors declared another quarterly dividend on Thursday of $0.39 per share. This dividend is payable on Dec. 12, 2019 to all shareholders of record as of Nov. 7, 2019. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends ResMed. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ResMed Inc. Stock Quote
ResMed Inc.
$234.70 (-0.72%) $-1.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.